chrisvoncsefalvay/vaers-outcomes huggingface dataset:
"Swollen limpth nodes"; Burning mouth; Legs hurt below knee; Headache; Body felt like heavy/led; Very tired; Arm muscle hurts; Under arm the gland is very tender.; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the right arm on 17Apr2021 at 09:15 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medications within two weeks prior to the COVID-19 vaccination. The patient previously received codeine (MANUFACTURER UNKNOWN) and experienced a drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the right arm on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 18Apr2021 at 08:30, the patient experienced "swollen limpth nodes", burning mouth, her legs hurt below the knee, headache, "body felt like heavy/led", very tired, her arm muscle hurt and she reported that she was on the third day after vaccine and was still tired and under arm the gland was very tender. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events "swollen limpth nodes", burning mouth, legs hurt below knee, headache, "body felt like heavy/led", very tired, arm muscle hurts and under arm the gland was very tender were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
3:00 pm headache,  4:30 high fever and chills,along with hands and feet feeling numb, 6:00 throwing up,weak and dizzy,  7:00 pm lips swollen, face swollen and shallow labored breathing and a fever of 103 F, called primary care physician on call and recommended immediate transport to emergency room.
ON 4/30/2008 PATIENT WAS SEEN BY CLINIC FOR PHYSICIAN AND SCHOOL FORMS.  RED SWOLLEN AREA (2 X 2 cm) NOTED ON PT'S LEFT ARM OUTER ASPECT.  PT C/O ITCHING.  AREA IS HOT TO THE TOUCH.  MOTHER INSTRUCTED TO APPLY COLD COMPRESS FOR 10 MIN ON AND 10 MIN OFF FOR 1 HOUR TO RELIEVE SWELLING AND PROVIDE COMFORT TO PT.  MOTHER STATED IT WAS FIRST NOTICED ON 4/29/2008.
Started with chills at 8 pm night of the 2nd vaccine; fever of 101 F started around 9 pm; aches and joint pain started thereafter.  Tossed all night from discomfort - woke up every hour.  Heart palpitations started around 1 am; took blood pressure is was 160/80 - felt like heart was beating out of my chest for several hours.  Nausea started thereafter but I did not get sick.  Left arm is much more painful than 1st shot.  Strong body aches and pains continue throughout night.  Almost went to ER for heart issue.  Fever at 3 am was 100 and at 8:30 am it is 99.8 and continues throughout morning.  Sluggish today, hard to move, exhausted.  Arm remains very tender.
itchiness; swelling; Redness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itchiness), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE ERYTHEMA (Redness) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Apr-2021, the patient experienced VACCINATION SITE PRURITUS (itchiness), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE ERYTHEMA (Redness). At the time of the report, VACCINATION SITE PRURITUS (itchiness), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE ERYTHEMA (Redness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product information, if any, was not provided by the reporter.  Treatment information, if any, was not provided.
rashes; This is a spontaneous report from a contactable consumer (patient) via a Regulatory Authority. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date: not reported), via an unspecified route of administration, on 08Mar2021, as DOSE 1, SINGLE for covid-19 immunization. The patient's medical history and concomitant medications were not reported. After first dose, the patient experienced rashes on an unspecified date in 2021.The patient was prescribed to take cephalexin. The patient will be taking his 2nd dose on 29Mar2021. The outcome of the event was unknown at time of report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt had HA and left hip pain after sitting in car. Vitals normal o2 sat 97%, HR 92 BP 121/69 noted. Pt was obs in car 20 minutes with pt calling and wanting to go home. No airway issues . Gave juice and patient felt better
Patient broke out into hives on her legs and back. Redness and itching occurred. No reaction occurred at the site of injection. Patient had previous tolerance to trivalent flu shot, but had not taken a quadravalent before.
10 days following vaccination with first dose of Pfizer-BioNTech vaccine, individual reported to the vaccine clinic that he developed symptoms of Bell's Palsy.  Specific symptoms included facial droop and inability to close eye on one side.  Individual sought urgent medical treatment and was diagnosed with Bell's Palsy and placed on a course of antiviral and steroids.  Individual was advised by outside provider to not receive second dose of vaccine.
Information has been received from an agency concerning a 9 year old female with no medical history and no drug allergies, who on 23-OCT-2007 was vaccinated intramuscularly in the left arm with a first dose of Gardasil (Lot# 654539/0742U).  There was no concomitant medication.  There were no illnesses at the time of the vaccination.  On 06-DEC-2007 the patient experienced bronchospasm.  On 26-DEC-2007 the patient was seen in the office for a new onset of moderate to severe exercise induced bronchospasm.  The patient had no atopic history, no history of eczema, asthma, and no family history.  The patient's symptoms developed about 6 weeks after receiving her first dose of the vaccination.  The patient was started on empiric therapy, yet the physician was concerned that her condition may have been prompted by the vaccination.  The patient's peak flows were normal at baseline and markedly diminished >50% with exercise, resulting in pallor, severe dyspnea, and wheezing after only minimal exertion in a previously healthy athletic child.  The patient was vaccinated with a second dose of Gardasil.  The physician was following her very closely.  At the time of the report, the patient's outcome was unknown.  The physician considered the bronchospasm to be life threatening.  The VAERS ID# is 301146.  A standard lot check investigation was performed.  All in-process quality checks for the lot number in question were satisfactory.  In addition, an expanded lot check investigation was performed.  The testing performed on the batch prior to release met all release specifications.  The lot met the requirements of the agency and was released.  Additional information is not expected.
face flushed which patient described that it felt like her face stung (had pain); face flushed which patient described that it felt like her face stung (had pain); This is a spontaneous report from a non-contactable consumer (patient). A 66-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN5318), via an unspecified route of administration, administered in the right arm on 29Jan2021 10:30 (at the age of 66-year-old) as single dose for covid-19 immunisation. Medical history included asthma, high blood pressure, high cholesterol, sulfa allergy and cobalt allergy. The patient was not pregnant at the time of vaccination. The patient did not have other vaccine in four weeks and did not have covid prior to vaccination. Concomitant medication included lisinopril (MANUFACTURER UNKNOWN); atorvastatin (LIPITOR [ATORVASTATIN]); azelastine (MANUFACTURER UNKNOWN); fluticasone (MANUFACTURER UNKNOWN); alendronate sodium (MANUFACTURER UNKNOWN); trazodone (MANUFACTURER UNKNOWN); gabapentin (MANUFACTURER UNKNOWN); montelukast sodium (SINGULAIR).  The patient experienced face flushed which patient described that it felt like her face stung (had pain) on 29Jan2021 10:30. It was reported that no treatment was given in response to the events. The patient was not tested for covid post vaccination. The patient recovered from the events on an unspecified date.   No follow-up attempts are possible. No further information is expected.
Dose 1 and 2 received on 04-FEB-2021 and 04-MAY-2021, 3 Months apart; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and 2 received on 04-FEB-2021 and 04-MAY-2021, 3 Months apart) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and 2 received on 04-FEB-2021 and 04-MAY-2021, 3 Months apart). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 and 2 received on 04-FEB-2021 and 04-MAY-2021, 3 Months apart) outcome was unknown.            It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No concomitant medication was reported by reporter. No treatment medication was reported by reporter.   This case was linked to MOD-2022-596093 (Patient Link).
This spontaneous report as received from a medical assistant refers to a currently 22 years old female patient with attention deficit disorder. The patient was vaccinated with MMR II (lot number, Albumin status of rHa or HAS were not reported) (dose, route and injection site were not known) on an unknown date. No other co-suspects were reported. Concomitant medication was ADDERALL tablets. On an unknown date the patient had a negative titer for rubella. The reporter thought the patient had received at least one dose of MMR II sometime in the past, but she did not have the vaccination records available at the time of report. There was no treatment given for the adverse event. Laboratory diagnostics rubella titers were performed and the results was negative. The present status of patient was reported as "rubella titer is negative". The patient had sought unspecified medical attention. Additional information has been requested.
My left arm is still hurting now, hot to the touch as I write this email. It has been hurting ever since I took that shot in my left arm. I went back for my second shot it went fine, took the shot in my right no problem, but something is definitely wrong with my left arm.
Information has been received from a lawyer regarding a case in litigation concerning a 77 year old female patient. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient was prescribed the ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 01-JUL-2009, at age 69, the patient was administered the ZOSTAVAX by a healthcare provider at a physician's office. On or about 01-MAR-2017, the patient was treated by a physician for the following injury resulting from her ZOSTAVAX use: Shingles. The outcome of the shingles is unknown. The patient claims damages as a result of: injury to herself, loss of consortium, loss of services, and economic losses. Additional information has been requested.
I got mine from a vaccine!/suspected vaccination failure; I got mine; sick; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and sickness. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles and sickness were not recovered/not resolved.   The reporter considered the vaccination failure, shingles and sickness to be related to Shingles vaccine.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient got the shingles from a vaccine and still had shingles 6 months later and he/she was sick of being sick. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were unknown at the time of reporting.
Patient suffered severe reaction day of MMR/DPT; 103 fever, cold symptoms, and rash covering body. Four weeks later to diagnosis on 8/12/99 bruises, boils, FTT, fevers. Bruises began to clot after long illness May 1999. Platelet count 5,000; admitted to hospital, reaction to IV. Platelets increased when wheat/gluten-free drip. Cannot eat wheat/gluten or platelets drop to 40K. Pt cannot eat wheat/gluten or her platelet count drops. Annual follow up on 02/18/04: "Pt has not recovered from adverse events. Pt is unable to eat wheat/gluten due to the damage to her gut as a result of the MMR.
Patient noticed immediate warmth traveling through arm and radiating up neck and face. She also tasted a metallic sensation. After 15 minutes she developed itching on her face and neck with hives developing. She felt a sensation of a "band around her neck" and described a sensation of something "sitting on the band".  At 10:15 we called EMS, administered an Epi Pen.  EMS service administered Zofran for nausea that occurred when she tried to sit up after lying flat. They also gave Benadryl.  She was transported the ER.
I developed and was diagnosed with shingles (diagnosed by a healthcare provider, I believe to be an NP, at Urgent Care)
second dose was not administered yet; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in 8th February 2018).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were reported as follows: The age at vaccination was not applicable for this report. The pharmacist reported that a male patient was late for the 2nd dose of Shingrix and 2nd dose was not administered till the time of reporting which led to incomplete course of vaccination. No adverse event was reported. No lot number and expiration date provided. The reporter consented to follow up.
moderate rash on bilateral forearms and elbows. Rash is red, raised and itchy.  rash appeared approximately 24 hours post vaccine injection. it has now been slightly over a week  and rash is still present. I have been taking Benadryl and Pepcid with some relief. I have also been using Benadryl cream while working.
T 102 within 24 hours of administration (about 12 hours after). Swollen, warm (L) thigh 3 cm larger in circumference than (R) leg. No site redness at 0930 10/3/12. T 100.3 after MOTRIN in office.
Fainted on way home after receiving vaccines. Was out for first a few seconds only. Then was nauseous, no vomiting. Was hungry shortly there after and did fine without other symptoms after that. No treatment.
No Adverse Event - patient filled out form and marked age as 12 and category for Pfizer as 12+ (vs 5-11). Upon documentation of the given vaccine, the vaccinator realized his age was 10 and not 12.
I am sicker now than when i had covid; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (I am sicker now than when i had covid) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in January 2021.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (I am sicker now than when i had covid). At the time of the report, ILLNESS (I am sicker now than when i had covid) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment information provided.   This case was linked to MOD-2021-162461.
shortly p/vax pt devel fever & irritability;  prolonged crying > 24 hrs; temp to 103 seen @ ER t39.1 down to 38.5, less irritable p/Ibuprofen;
Fever, irritability, fatigue, decreased activity and appetite for 4 - 8 days after receiving DTaP. Child has history of immunodeficiency (IgG and IgA). Was given DTaP on 6/22/07. Prior to that patient was given DT on 5/22/07 and 12/28/06, 3/28/06, 1/20/06, 11/24/05
2 weeks later he was diagnosed from 3rd cranial nerve palsy; sinus infection; This spontaneous case was reported by a consumer and describes the occurrence of IIIRD NERVE PARALYSIS (2 weeks later he was diagnosed from 3rd cranial nerve palsy) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IIIRD NERVE PARALYSIS (2 weeks later he was diagnosed from 3rd cranial nerve palsy) (seriousness criterion medically significant) and SINUSITIS (sinus infection). At the time of the report, IIIRD NERVE PARALYSIS (2 weeks later he was diagnosed from 3rd cranial nerve palsy) and SINUSITIS (sinus infection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.  Company Comment:  Very limited information regarding this event/s has been provided at this time. Further information has been requested.; Sender's Comments: Very limited information regarding this event/s has been provided at this time. Further information has been requested.
Redness at and around injection site. Swelling, tenderness, warmth, itching, malaise, lethargy.
Arm Soreness; Swollen Lymph Node; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm Soreness), LYMPHADENOPATHY (Swollen Lymph Node) and FATIGUE (Fatigue) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced PAIN IN EXTREMITY (Arm Soreness), LYMPHADENOPATHY (Swollen Lymph Node) and FATIGUE (Fatigue). On 05-Feb-2021, PAIN IN EXTREMITY (Arm Soreness), LYMPHADENOPATHY (Swollen Lymph Node) and FATIGUE (Fatigue) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.   This case was linked to MOD21-021739, MOD21-021736, MOD21-021738, MOD-2021-021800 (Patient Link).
Large red spot at injection site which was hot to the touch and itchy.  It remained that way for 3 weeks
Information has been received from a published literature article. The patient in this case was a 3 year-old girl with hepatoblastoma. She also had a genetic condition, known as mosaic trisomy 17. Of note, she received varicella vaccine (manufacturer unknown, lot #, dose and route were not reported) when she was 13 months old; however, her screening Varicella-Zoster Virus (VZV)-specific IgG/IgM (ELISA) titers were undetectable when she developed varicella at age 3 years. We defined the day when she developed fever and became critically ill as Day 1. About 1 month prior to this febrile episode, she had been diagnosed with an undifferentiated hepatoblastoma. During her initial chemotherapy regimen, she developed acute kidney injury and a low white blood cell count. She was treated with granulocyte colony stimulation factor. Subsequently, the regimen was switched to vincristine, cisplatin, and doxorubicin, leading to a persistent lymphocytopenia (less than 1000 count/mm2). After she developed fever with neutropenia, she was admitted on day 1 for treatment with antibiotics as per protocol. On Day 2, she developed a vesicular rash on the legs. When VZV antigen was identified by immunostaining cells from a vesicle, she was started on intravenous acyclovir (50 mg/kg/day). Despite treatment, the rash worsened and spread over the next 5 days onto the lower abdomen (the rash, even at onset, never had a zosteriform distribution). The diagnosis of VZV infection was confirmed by polymerase chain reaction (PCR) analysis from deoxyribonucleic acid (DNA) extracted from peripheral white blood cells collected on Day 3. Testing was performed on blood cells to document a persistent viremia while on antiviral therapy. The strain was confirmed as wild type VZV. Fevers continued for 5 days. She finally defervesced with no new lesions on Day 8. Overall, a prolonged course of intravenous acyclovir was continued until Day 19, followed by oral acyclovir (70 mg/kg/day) as suppression therapy for 3 months. Suppressive therapy was lengthy because of a previous case report of recurrence of breakthrough disease in a cancer patient when antiviral therapy was halted too quickly. The source of the VZV infection was never identified. The authors considered the event to be vaccination failure and to be life-threatening. This is one of 2 reports received from the same literature (other case # 1505USA000487). Additional information has been requested.
Chills, aches, high blood pressure, heart racing, tired, flu sick feel, asthma Jan 14th, 2nd day: face swollen, blotchy, numb eyes swollen, sore sockets, upper lip puffed out, burning face feel, asthma